453,700 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 453,700 shares of the company’s stock, valued at approximately $9,995,000. Raymond James Financial Inc. owned approximately 0.22% of Cellebrite DI at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Aigen Investment Management LP grew its stake in Cellebrite DI by 16.9% during the 4th quarter. Aigen Investment Management LP now owns 52,595 shares of the company’s stock valued at $1,159,000 after acquiring an additional 7,598 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Cellebrite DI during the 4th quarter valued at about $234,000. Steward Partners Investment Advisory LLC grew its stake in Cellebrite DI by 12.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock valued at $299,000 after acquiring an additional 1,463 shares in the last quarter. Tower View Wealth Management LLC grew its stake in Cellebrite DI by 1.3% during the 4th quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company’s stock valued at $2,915,000 after acquiring an additional 1,660 shares in the last quarter. Finally, True Wind Capital Management L.P. grew its stake in Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after acquiring an additional 2,130,386 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $19.23 on Friday. The business’s fifty day moving average price is $21.12 and its two-hundred day moving average price is $19.76. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The stock has a market capitalization of $4.61 billion, a price-to-earnings ratio of -13.83, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Lake Street Capital lifted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a report on Monday, March 10th. Finally, JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI presently has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.